CoChat
Sign Up
Cited by 384Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

Open access
Bertrand, Florie, Montfort, Anne, Marcheteau, Elie, Imbert, Caroline, Gilhodes, Julia, Filleron, Thomas, Rochaix, Philippe, Andrieu-Abadie, Nathalie, Levade, Thierry, Meyer, Nicolas, Colacios, Céline, Ségui, Bruno·2017·Nature Communications
DOI 10.1038/s41467-017-02358-7PMC PMC5741628
Open this paper in CoChat — free accountOpen PDF

Abstract

Antibodies against programmed cell death-1 (PD-1) have considerably changed the treatment for melanoma. However, many patients do not display therapeutic response or eventually relapse. Moreover, patients treated with anti-PD-1 develop immune-related adverse events that can be cured with anti-tumor necrosis factor α (TNF) antibodies. Whether anti-TNF antibodies affect the anti-cancer immune response remains unknown. Our recent work has highlighted that TNFR1-dependent TNF signalling impairs the accumulation of CD8+ tumor-infiltrating T lymphocytes (CD8+ TILs) in mouse melanoma. Herein, our results indicate that TNF or TNFR1 blockade synergizes with anti-PD-1 on anti-cancer immune responses towards solid cancers. Mechanistically, TNF blockade prevents anti-PD-1-induced TIL cell death as well as PD-L1 and TIM-3 expression. TNF expression positively correlates with expression of PD-L1 and TIM-3 in human melanoma specimens. This study provides a strong rationale to develop a combination therapy based on the use of anti-PD-1 and anti-TNF in cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-02358-7

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 TNF deficiency enhances anti-PD-1 response in a mouse melanoma model. C57BL/6 wild-type (WT) and TNF-deficient (TNF−/−) mice were intradermally and bilaterally grafted with 3 × 105 (a–c) (n = 11 mice per group) or 1 × 106 (d–f) (n = 6 mice per group). B16K1 melanoma cells prior to intraperitoneal injection of anti-PD-1 antibodies (αPD-1, 10 mg kg−1) or a relevant isotype control (Iso, 10 mg kg−1) at days 6, 10 and 13. a and d Tumor volumes were determined with a calliper. Individual curves are depicted for each tumor. Numbers indicate complete tumor regression out of total tumors. Data are from three independent experiments. b and e Tumor volumes determined at the indicated days for individual tumors are depicted. Bars represent mean values ± s.e.m. (Mann–Whitney U test: *p < 0.05; **p < 0.01; ***p < 0.001). c and f Cumulative survival curves (Logrank test: *p < 0.05; **p < 0.01; ***p < 0.001). At day 60, surviving mice were challenged with a second B16K1 injection as indicated by the arrow; mice did not develop tumors and survived (c)
Fig. 1 TNF deficiency enhances anti-PD-1 response in a mouse melanoma model. C57BL/6 wild-type (WT) and TNF-deficient (TNF−/−) mice were intradermally and bilaterally grafted with 3 × 105 (a–c) (n = 11 mice per group) or 1 × 106 (d–f) (n = 6 mice per group). B16K1 melanoma cells prior to intraperitoneal injection of anti-PD-1 antibodies (αPD-1, 10 mg kg−1) or a relevant isotype control (Iso, 10 mg kg−1) at days 6, 10 and 13. a and d Tumor volumes were determined with a calliper. Individual curves are depicted for each tumor. Numbers indicate complete tumor regression out of total tumors. Data are from three independent experiments. b and e Tumor volumes determined at the indicated days for individual tumors are depicted. Bars represent mean values ± s.e.m. (Mann–Whitney U test: *p < 0.05; **p < 0.01; ***p < 0.001). c and f Cumulative survival curves (Logrank test: *p < 0.05; **p < 0.01; ***p < 0.001). At day 60, surviving mice were challenged with a second B16K1 injection as indicated by the arrow; mice did not develop tumors and survived (c)CC BY · PubMed Central
Fig. 2 Immune cell infiltration of tumors from anti-PD-1 treated wild-type and TNF-deficient mice with established melanoma. a–c, C57BL/6 wild-type (WT) and TNF-deficient (TNF−/−) mice were intradermally and bilaterally grafted with 1 × 106 B16K1 melanoma cells prior to intraperitoneal injection of anti-PD-1 antibodies (αPD-1, 10 mg kg−1) or vehicle (PBS) at day 7. a At day 10, mice were sacrificed and tumors were weighed. Data are means ± s.e.m. of at least 22 tumors per group from two independent experiments (Student’s t-test: *p < 0.05; ***p < 0.001). b and c TIL content was analysed by flow cytometry. The proportion of CD45+ and Thy1+ cells (b) CD4+ and CD8+ TILs (c) among total cells was determined. Data are means ± s.e.m. of at least 11 tumors per group from two independent experiments (Mann–Whitney U test: *p < 0.05; **p < 0.01; ***p < 0.001). d Proportion of dead CD8+ and CD4+ TILs from WT and TNF-deficient mice treated with anti-PD-1. Left panels: representative stainings. Right panels: values measured in 12 tumors per group from two independent experiments are represented as Tukey boxes (Student’s t-test: *p < 0.05; ***p < 0.001)
Fig. 2 Immune cell infiltration of tumors from anti-PD-1 treated wild-type and TNF-deficient mice with established melanoma. a–c, C57BL/6 wild-type (WT) and TNF-deficient (TNF−/−) mice were intradermally and bilaterally grafted with 1 × 106 B16K1 melanoma cells prior to intraperitoneal injection of anti-PD-1 antibodies (αPD-1, 10 mg kg−1) or vehicle (PBS) at day 7. a At day 10, mice were sacrificed and tumors were weighed. Data are means ± s.e.m. of at least 22 tumors per group from two independent experiments (Student’s t-test: *p < 0.05; ***p < 0.001). b and c TIL content was analysed by flow cytometry. The proportion of CD45+ and Thy1+ cells (b) CD4+ and CD8+ TILs (c) among total cells was determined. Data are means ± s.e.m. of at least 11 tumors per group from two independent experiments (Mann–Whitney U test: *p < 0.05; **p < 0.01; ***p < 0.001). d Proportion of dead CD8+ and CD4+ TILs from WT and TNF-deficient mice treated with anti-PD-1. Left panels: representative stainings. Right panels: values measured in 12 tumors per group from two independent experiments are represented as Tukey boxes (Student’s t-test: *p < 0.05; ***p < 0.001)CC BY · PubMed Central
Fig. 3 Anti-PD-1 triggers TIM-3 expression on CD8+ TILs in a TNF-dependent manner. WT and TNF-deficient mice were injected as described in the legend to Fig. 2. TIM-3 and PD-1 expression on CD8+ TILs was determined by flow cytometry at day 10. a Representative staining; values indicate the proportion of cells in the different quadrants. b Quantification of the proportion of TIM-3+ (left panel) and PD-1+ (right panel) among CD8+ TILs. c Quantification of the proportion of CD8+ TILs expressing or not TIM-3 and PD-1 (left panel), and proportion of cell death among CD8+ T cells of the indicated populations (right panel). Values in 5–6 mice per group from one experiment are represented as Tukey boxes (b: Student’s t-test: **p < 0.01; c: two-way Anova: ***p < 0.001). d Representative histograms of live/dead staining in CD8+ TILs expressing both TIM-3 and PD-1. Values are percentages of dead cells among the TIM-3+ PD-1+ CD8+ TILs
Fig. 3 Anti-PD-1 triggers TIM-3 expression on CD8+ TILs in a TNF-dependent manner. WT and TNF-deficient mice were injected as described in the legend to Fig. 2. TIM-3 and PD-1 expression on CD8+ TILs was determined by flow cytometry at day 10. a Representative staining; values indicate the proportion of cells in the different quadrants. b Quantification of the proportion of TIM-3+ (left panel) and PD-1+ (right panel) among CD8+ TILs. c Quantification of the proportion of CD8+ TILs expressing or not TIM-3 and PD-1 (left panel), and proportion of cell death among CD8+ T cells of the indicated populations (right panel). Values in 5–6 mice per group from one experiment are represented as Tukey boxes (b: Student’s t-test: **p < 0.01; c: two-way Anova: ***p < 0.001). d Representative histograms of live/dead staining in CD8+ TILs expressing both TIM-3 and PD-1. Values are percentages of dead cells among the TIM-3+ PD-1+ CD8+ TILsCC BY · PubMed Central
Fig. 4 TNF induces TIM-3 expression on CD8+ T cells ex vivo. a WT or TNFR1-deficient CD8+ T cells were incubated with murine TNF for 2 days. TIM-3 expression was next analysed by flow cytometry. Upper panels: representative histograms. Lower panel: data are means ± s.e.m. of three independent experiments. b and c TILs from two human metastatic melanoma patients were cultured with or without autologous melanoma cells for two days in the presence 200 U ml−1 IL-2 +/−50 ng ml−1 human TNF. TIM-3 expression was next analysed by flow cytometry: histograms showing TIM-3 staining on TILs from patient 1 (b); bar graph depicting the fold increase in TIM-3 expression on TILs from patients 1 and 2 (c)
Fig. 4 TNF induces TIM-3 expression on CD8+ T cells ex vivo. a WT or TNFR1-deficient CD8+ T cells were incubated with murine TNF for 2 days. TIM-3 expression was next analysed by flow cytometry. Upper panels: representative histograms. Lower panel: data are means ± s.e.m. of three independent experiments. b and c TILs from two human metastatic melanoma patients were cultured with or without autologous melanoma cells for two days in the presence 200 U ml−1 IL-2 +/−50 ng ml−1 human TNF. TIM-3 expression was next analysed by flow cytometry: histograms showing TIM-3 staining on TILs from patient 1 (b); bar graph depicting the fold increase in TIM-3 expression on TILs from patients 1 and 2 (c)CC BY · PubMed Central
Fig. 5 Anti-TNF treatment enhances anti-PD-1 response in a mouse melanoma model. C57BL/6 wild-type (WT) mice were intradermally grafted with 3 × 105 B16K1 melanoma cells followed by intraperitoneal injection of anti-TNF antibodies (αTNF, 10 mg kg−1) or vehicle (PBS) at days 6, 9, 13 and 16 and/or anti-PD-1 (10 mg kg−1) at days 6, 9 and 13 (n = 12 mice per group). Data are from two independent experiments. a Individual tumor volumes are depicted. Numbers indicate complete tumor regression out of total tumors. b Cumulative survival curves. At day 60, (arrow) surviving mice were challenged with a second B16K1 injection; these mice did not develop tumors and survived (Logrank test: **p < 0.01; ***p < 0.001). c and d C57BL/6 WT mice were intradermally and bilaterally grafted with 1 × 106 B16K1 melanoma cells prior to intraperitoneal injection of anti-TNF (αTNF, 10 mg kg−1) or vehicle at days 5 and 7, and with anti-PD-1 antibodies (αPD-1, 10 mg kg−1) or vehicle (PBS) at day 7. At day 10, CD8+ TILs (c) and the proportion of cell death in CD8+ TILs (d) were analysed by flow cytometry. Data from at least 5 tumors per group are represented as Tukey boxes (Mann–Whitney U test: *p < 0.05; **p < 0.01)
Fig. 5 Anti-TNF treatment enhances anti-PD-1 response in a mouse melanoma model. C57BL/6 wild-type (WT) mice were intradermally grafted with 3 × 105 B16K1 melanoma cells followed by intraperitoneal injection of anti-TNF antibodies (αTNF, 10 mg kg−1) or vehicle (PBS) at days 6, 9, 13 and 16 and/or anti-PD-1 (10 mg kg−1) at days 6, 9 and 13 (n = 12 mice per group). Data are from two independent experiments. a Individual tumor volumes are depicted. Numbers indicate complete tumor regression out of total tumors. b Cumulative survival curves. At day 60, (arrow) surviving mice were challenged with a second B16K1 injection; these mice did not develop tumors and survived (Logrank test: **p < 0.01; ***p < 0.001). c and d C57BL/6 WT mice were intradermally and bilaterally grafted with 1 × 106 B16K1 melanoma cells prior to intraperitoneal injection of anti-TNF (αTNF, 10 mg kg−1) or vehicle at days 5 and 7, and with anti-PD-1 antibodies (αPD-1, 10 mg kg−1) or vehicle (PBS) at day 7. At day 10, CD8+ TILs (c) and the proportion of cell death in CD8+ TILs (d) were analysed by flow cytometry. Data from at least 5 tumors per group are represented as Tukey boxes (Mann–Whitney U test: *p < 0.05; **p < 0.01)CC BY · PubMed Central
Fig. 6 TNF blockade prevents TIM-3 up-regulation on TILs in response to anti-PD-1. WT mice were injected as described in the legend to Fig. 5. a–c TIM-3 expression level on CD8+ TILs and CD4+ TILs was determined by flow cytometry on tumors from WT mice at day 10 after B16K1 graft following injection of vehicle (PBS), anti-PD-1 (αPD-1), anti-TNF (αTNF) or a combination of both. Representative stainings (a) mean fluorescence intensity (MFI) of TIM-3 on CD8+ (b) and CD4+ TILs (c) measured in at least 5 tumors per group from one experiment are represented as Tukey boxes. b, c: Mann–Whitney U test: *p < 0.05; **p < 0.01; ***p < 0.001). d and e C57BL/6 WT mice were intradermally and bilaterally grafted with 3 × 105 B16K1 melanoma cells prior to injection with vehicle, anti-PD-1 alone or combined with anti-TNF and/or anti-TIM-3 (10 mg kg−1 of each antibody) at days 6, 10, and 13 (d) (PBS (n = 12), αPD-1 (n = 9), αPD-1 + αTNF (n = 14), αPD-1 + αTIM-3 (n = 13), αPD-1 + αTNF + αTIM-3 (n = 15), data from two experiments) or at days 13, 16, and 19 (e) (n = 10 mice per group, data from one representative experiment out of two). Tumor volumes were determined with a calliper. Data are means ± s.e.m. (d) and e, two-way Anova: **p < 0.01, ***p < 0.001 at day 35 (d) and day 21 (e); p = 0.08 at day 35 when comparing anti-PD-1 alone and anti-PD-1 plus anti-TIM-3 (d)
Fig. 6 TNF blockade prevents TIM-3 up-regulation on TILs in response to anti-PD-1. WT mice were injected as described in the legend to Fig. 5. a–c TIM-3 expression level on CD8+ TILs and CD4+ TILs was determined by flow cytometry on tumors from WT mice at day 10 after B16K1 graft following injection of vehicle (PBS), anti-PD-1 (αPD-1), anti-TNF (αTNF) or a combination of both. Representative stainings (a) mean fluorescence intensity (MFI) of TIM-3 on CD8+ (b) and CD4+ TILs (c) measured in at least 5 tumors per group from one experiment are represented as Tukey boxes. b, c: Mann–Whitney U test: *p < 0.05; **p < 0.01; ***p < 0.001). d and e C57BL/6 WT mice were intradermally and bilaterally grafted with 3 × 105 B16K1 melanoma cells prior to injection with vehicle, anti-PD-1 alone or combined with anti-TNF and/or anti-TIM-3 (10 mg kg−1 of each antibody) at days 6, 10, and 13 (d) (PBS (n = 12), αPD-1 (n = 9), αPD-1 + αTNF (n = 14), αPD-1 + αTIM-3 (n = 13), αPD-1 + αTNF + αTIM-3 (n = 15), data from two experiments) or at days 13, 16, and 19 (e) (n = 10 mice per group, data from one representative experiment out of two). Tumor volumes were determined with a calliper. Data are means ± s.e.m. (d) and e, two-way Anova: **p < 0.01, ***p < 0.001 at day 35 (d) and day 21 (e); p = 0.08 at day 35 when comparing anti-PD-1 alone and anti-PD-1 plus anti-TIM-3 (d)CC BY · PubMed Central
Fig. 7 TNF expression is associated with an immune escape gene signature in human metastatic melanoma. a Heatmap for a selected list of genes encoding immune escape proteins in metastatic melanoma patients from the TCGA melanoma cohort (n = 342), exhibiting high (80th percentile) and low (20th percentile) TNF expression in melanoma samples. Genes were clustered using a Euclidean distant matrix and average linkage clustering. b and c Correlation analysis between the expression of HAVCR2 (encoding TIM-3), PDCD1LG1 (encoding PD-L1), PDCD1LG2 (encoding PD-L2) and TNFA (encoding TNF) in melanoma samples from metastatic melanoma patients from the TCGA cohort (n = 342) (b) and from patients treated with anti-PD-1 (our analysis of data published in ref.23) (n = 13) (c)
Fig. 7 TNF expression is associated with an immune escape gene signature in human metastatic melanoma. a Heatmap for a selected list of genes encoding immune escape proteins in metastatic melanoma patients from the TCGA melanoma cohort (n = 342), exhibiting high (80th percentile) and low (20th percentile) TNF expression in melanoma samples. Genes were clustered using a Euclidean distant matrix and average linkage clustering. b and c Correlation analysis between the expression of HAVCR2 (encoding TIM-3), PDCD1LG1 (encoding PD-L1), PDCD1LG2 (encoding PD-L2) and TNFA (encoding TNF) in melanoma samples from metastatic melanoma patients from the TCGA cohort (n = 342) (b) and from patients treated with anti-PD-1 (our analysis of data published in ref.23) (n = 13) (c)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 384

Related

See all

Metadata

Authors
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., Colacios, C., & Ségui, B.
Affiliations
  • Inserm (FR)
  • Université Toulouse III - Paul Sabatier (FR)
Corresponding author
Ségui, Bruno
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2017-12-22
Volume
8
Issue
1
Pages
2256-2256
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-017-02358-7
PMC
PMC5741628
OpenAlex
W2779658193
Cited by
384
References
46
Citations by year
2026: 32 · 2025: 36 · 2024: 44 · 2023: 44 · 2022: 49 · 2021: 50 · 2020: 82 · 2019: 29 · 2018: 17
FWCI
15.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Institut National de la Santé et de la Recherche Médicale (INSERM U1048, U1043, U1048)
  • Institut National Du Cancer
  • Fondation Toulouse Cancer Santé
  • Inserm Transfert
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
anti-PD-1 therapy, melanoma, immune checkpoint inhibitor resistance, TNFR1 signaling, tumor-infiltrating lymphocytes, CD8+ T cells, PD-L1, TIM-3, combination immunotherapy, immune-related adverse events, cancer immunotherapy
MeSH terms
Hepatitis A Virus Cellular Receptor 2, Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Animals, Antibodies, Monoclonal, Drug Synergism, Female, Humans, Melanoma, Melanoma, Experimental, Skin Neoplasms, Tumor Necrosis Factor-alpha, Mammary Neoplasms, Animal, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Cell Line, Tumor, Receptors, Tumor Necrosis Factor, Type I, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review